1.41

2.17% 0.03

Traws Pharma Inc (TRAW)

Overview News Price History Discussions Forecast

Traws Pharma Inc stock is traded at $1.41, with a volume of 71,142. It is up +2.17% in the last 24 hours and down -12.96% over the past month. Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.

Previous Close:

$1.38

Open:

$1.37

24h Volume:

71,142

Relative Volume:

0.06

Market Cap:

$9.96M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-6.62%

1M Performance:

-12.96%

6M Performance:

-68.53%

1Y Performance:

-84.11%

1-Day Range:

$1.35

$1.42

1-Week Range:

$1.26

$1.58

52-Week Range:

$0.97

$19.44

Traws Pharma Inc Stock (TRAW) Company Profile

Name

Traws Pharma Inc

Sector

Healthcare (1157)

Industry

Biotechnology (645)

Phone

267-759-3680

Address

12 PENNS TRAIL, NEWTOWN

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TRAW's Discussions on Twitter

Compare TRAW with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRAW Traws Pharma Inc	1.41	7.90M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	395.12	99.96B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	589.48	60.83B	14.21B	4.46B	3.56B	39.68
ALNY Alnylam Pharmaceuticals Inc	454.38	59.89B	2.46B	-319.09M	-52.09M	-2.47
ARGX Argen X Se Adr	660.00	40.47B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	313.67	37.96B	3.81B	-644.79M	-669.77M	-6.24

Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-01-22	Initiated	Ladenburg Thalmann	Buy
May-18-21	Initiated	Guggenheim	Buy
Mar-01-18	Reiterated	H.C. Wainwright	Buy
Jan-17-18	Downgrade	Maxim Group	Buy → Hold
Oct-09-17	Initiated	H.C. Wainwright	Buy
Apr-27-17	Initiated	Laidlaw	Buy
Jul-01-15	Upgrade	Piper Jaffray	Neutral → Overweight
May-05-15	Initiated	H.C. Wainwright	Buy

View All

Traws Pharma Inc Stock (TRAW) Latest News

Aug 20, 2025

Comparing Traws Pharma Inc. in custom built stock radarsEarnings Beat & Daily Technical Stock Forecast Reports - Newser

Aug 20, 2025

What high frequency data says about Traws Pharma Inc.Market Performance Summary & Fast Moving Stock Watchlists - Newser

Aug 20, 2025

How to build a dashboard for Traws Pharma Inc. stockJobs Report & Weekly Breakout Opportunity Watchlist - Newser

Aug 20, 2025

How to read the order book for Traws Pharma Inc.2025 AllTime Highs & Accurate Trade Setup Notifications - Newser

Aug 20, 2025

Evaluating Traws Pharma Inc. with trendline analysisEarnings Beat & Technical Pattern Alert System - Newser

Aug 20, 2025

Aug 19, 2025

How to interpret RSI for Traws Pharma Inc. stockQuarterly Trade Summary & Risk Managed Investment Signals - Newser

Aug 19, 2025

Is Traws Pharma Inc. stock entering bullish territoryWeekly Trend Summary & Advanced Swing Trade Entry Alerts - Newser

Aug 19, 2025

What machine learning models say about Traws Pharma Inc.Oil Prices & Fast Entry and Exit Trade Plans - Newser

Aug 19, 2025

Has Traws Pharma Inc. found a price floorQuarterly Portfolio Report & AI Enhanced Trade Execution Alerts - Newser

Aug 19, 2025

Aug 18, 2025

Will Traws Pharma Inc. outperform its industry peersJuly 2025 Trade Ideas & Risk Managed Investment Strategies - thegnnews.com

Aug 18, 2025

Traws Pharma receives approval to proceed with Phase 2 COVID studies - TipRanks

Aug 18, 2025

Traws Pharma Gains Approval for Phase 2 COVID-19 Trials - TipRanks

Aug 18, 2025

Traws Pharma's Ratutrelvir and the Disruption of the $427M Q2 PAXLOVID Market - AInvest

Aug 18, 2025

Traws Pharma begins Phase 2 trials for ritonavir-free COVID treatment - Investing.com

Aug 18, 2025

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 | TRAW Stock News - GuruFocus

Aug 18, 2025

Traws Pharma Receives Approval to Proceed with Phase 2 - GlobeNewswire

Aug 18, 2025

Traws Pharma, Inc. Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 - MarketScreener

Aug 18, 2025

Traws Pharma Reports Q2 Results, Advances COVID-19 and Influenza Antiviral Programs - MSN

Aug 18, 2025

How to integrate Traws Pharma Inc. into portfolio analysis toolsMarket Sentiment Review & Safe Capital Preservation Plans - Newser

Aug 18, 2025

Can a trend reversal in Traws Pharma Inc. lead to recoveryDollar Strength & AI Enhanced Trading Alerts - Newser

Aug 18, 2025

Aug 17, 2025

Best data tools to analyze Traws Pharma Inc. stockMarket Sentiment Review & Weekly High Conviction Trade Ideas - Newser

Aug 17, 2025

Using R and stats models for Traws Pharma Inc. forecastingJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - Newser

Aug 17, 2025

Analysts Apply Wyckoff Model to Traws Pharma Inc. StockWeekly Trading Summary & AI Based Buy/Sell Signal Reports - metal.it

Aug 17, 2025

Aug 16, 2025

Traws Pharma, Inc. (NASDAQ:TRAW) Q2 2025 Earnings Call Transcript - MSN

Aug 16, 2025

Aug 15, 2025

What to expect from Traws Pharma Inc. in the next 30 days2025 Winners & Losers & Long-Term Growth Plans - Newser

Aug 15, 2025

How to monitor Traws Pharma Inc. with trend dashboardsWeekly Investment Summary & Expert Approved Trade Ideas - Newser

Aug 15, 2025

Using Python tools to backtest Traws Pharma Inc. strategiesMarket Growth Report & Risk Managed Investment Entry Signals - Newser

Aug 15, 2025

Can machine learning forecast Traws Pharma Inc. recoveryWeekly Trend Report & Low Drawdown Investment Strategies - Newser

Aug 15, 2025

Traws Pharma shares fall 6.48% intraday after reporting second quarter 2025 results. - AInvest

Aug 15, 2025

Traws Pharma Posts Q2 Revenue Jump - AOL.com

Aug 15, 2025

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - MarketScreener

Aug 15, 2025